Enovix Quarterly Cash Flow Statements Chart
Quarterly
|
Annual
Enovix Quarterly Cash Flow Statements Table
Quarterly
|
Annual
| Unit: USD | 2024-12-29 | 2024-03-31 | 2023-12-31 | 2023-04-02 | 2022-01-01 | 2021-10-03 | 2021-06-30 | 2021-03-31 |
|---|---|---|---|---|---|---|---|---|
| cash flows used in operating activities: | ||||||||
| net income | -37,452,000 | -46,497,000 | -60,038,000 | -73,603,000 | -10,316,000 | 128,186,004 | -118,139,039 | -51,352,965 |
| adjustments to reconcile net income to net cash from operating activities | ||||||||
| depreciation, accretion and amortization | 7,544,000 | 24,974,000 | ||||||
| stock-based compensation | 10,207,000 | 12,760,000 | 11,620,000 | 29,157,000 | ||||
| changes in fair value of common stock warrants | -21,120,000 | |||||||
| gain on bargain purchase of assets | ||||||||
| impairment and loss on disposal of long-lived assets | 9,000 | |||||||
| others | 274,000 | 173,000 | ||||||
| changes in operating assets and liabilities: | ||||||||
| accounts and notes receivables | -2,959,000 | 505,000 | ||||||
| inventory | 1,900,000 | 2,202,000 | 4,091,000 | -181,000 | ||||
| prepaid expenses and other assets | 1,702,000 | -1,809,000 | -1,172,000 | 364,000 | -1,183,000 | |||
| accounts payable | 2,048,000 | -7,281,000 | 1,758,000 | -1,792,000 | 2,629,000 | |||
| accrued expenses and compensation | -159,000 | 2,845,000 | -1,136,000 | 3,858,000 | -626,000 | |||
| deferred revenue | -2,556,000 | -1,402,000 | -6,381,000 | |||||
| deferred tax liability | 606,000 | -222,000 | ||||||
| other liabilities | -2,237,000 | -172,000 | 189,000 | -1,000 | -498,000 | |||
| net cash from operating activities | -15,958,000 | -35,044,000 | -27,228,000 | -25,611,000 | -48,226,000 | -33,850,011 | -173,704 | -490,285 |
| capex | -16,358,000 | 433,000 | -28,816,000 | 1,708,000 | -4,703,000 | 0 | 0 | 0 |
| free cash flows | -32,316,000 | -34,611,000 | -56,044,000 | -23,903,000 | -52,929,000 | -33,850,011 | -173,704 | -490,285 |
| cash flows from investing activities: | ||||||||
| purchase of property and equipment | -16,358,000 | -15,088,000 | -28,816,000 | -3,032,000 | -4,703,000 | |||
| payment for business acquisition | ||||||||
| purchases of investments | 0 | -17,066,000 | -22,607,000 | |||||
| maturities of investments | 0 | 51,260,000 | 50,450,000 | |||||
| net cash from investing activities | -16,358,000 | 19,106,000 | -10,941,000 | -3,032,000 | -4,703,000 | -31,542,846 | 11,554 | 22,292 |
| cash flows from financing activities: | ||||||||
| proceeds from loan borrowing | 1,800,000 | |||||||
| repayment of debt | -29,000 | |||||||
| payroll tax payments for shares withheld upon vesting of rsus | -1,478,000 | -2,222,000 | -943,000 | -777,000 | ||||
| proceeds from the exercise of stock options and issuance of common stock under atm, net of issuance costs | ||||||||
| proceeds from issuance of common stock under employee stock purchase plan | 361,000 | 1,181,000 | ||||||
| payments of transaction costs related to common stock issuance | ||||||||
| repurchase of unvested restricted common stock | 0 | -3,000 | -9,000 | 3,000 | ||||
| net cash from financing activities | 106,532,000 | 5,430,000 | 2,196,000 | -457,000 | -319,166,000 | |||
| effect of exchange rate changes on cash, cash equivalents and restricted cash | -2,472,000 | -541,000 | ||||||
| change in cash, cash equivalents, and restricted cash | 71,744,000 | -11,049,000 | -35,819,000 | -29,100,000 | -372,095,000 | |||
| cash and cash equivalents and restricted cash, beginning of period | 0 | 235,123,000 | 0 | 322,976,000 | 356,200,000 | |||
| cash and cash equivalents and restricted cash, end of period | ||||||||
| payment of acquisition costs | ||||||||
| cash and cash equivalents, and restricted cash, end of period | 71,744,000 | 224,074,000 | -35,819,000 | 293,876,000 | -15,895,000 | |||
| change in fair value of common stock warrants | ||||||||
| routejade acquisition, net of cash and restricted cash acquired | ||||||||
| proceeds from issuance of common stock, net of issuance costs | ||||||||
| proceeds from exercise of common stock warrants, net and convertible preferred stock warrants | ||||||||
| proceeds from issuance of convertible senior notes and loans | ||||||||
| purchase of capped calls | 0 | |||||||
| payments of debt issuance costs | -666,000 | |||||||
| proceeds from loan borrowing and issuance of convertible senior notes | ||||||||
| proceeds from the exercise of stock options and issuance of common stock, net of issuance costs | 5,852,000 | |||||||
| supplemental cash flow disclosure: | ||||||||
| cash paid for interest | 23,000 | |||||||
| cash paid for income taxes | 88,000 | |||||||
| supplemental non-cash investing and financing activities: | ||||||||
| purchase of property and equipment included in liabilities | 15,521,000 | 4,740,000 | ||||||
| change in fair value of common stock warrants and convertible preferred stock warrants | ||||||||
| impairment of equipment | 0 | |||||||
| proceeds from business combination and pipe financing | ||||||||
| proceeds from issuance of convertible senior notes and secured promissory note | ||||||||
| proceeds from the exercise of stock options | 2,696,000 | 329,000 | 2,216,000 | |||||
| cash flows from operating activities: | ||||||||
| depreciation | 3,455,000 | 6,751,000 | ||||||
| amortization of right-of-use assets | 143,000 | 159,000 | ||||||
| accretion of discount on investments | ||||||||
| amortization of debt issuance costs | ||||||||
| accounts receivable | 149,000 | |||||||
| deferred contract costs | 5,033,000 | |||||||
| proceeds from exercise of common stock warrants | ||||||||
| proceeds from issuance of convertible senior notes | ||||||||
| changes in fair value of convertible preferred stock warrants and common stock warrants | 12,840,000 | -71,501,000 | ||||||
| supplemental cash flow data | ||||||||
| loss on early debt extinguishment | ||||||||
| payments of transaction costs related to business combination and pipe financing | ||||||||
| proceeds from secured promissory notes, converted promissory notes and paycheck protection program loan | ||||||||
| repayment of secured promissory note | ||||||||
| payment of debt issuance costs | ||||||||
| proceeds from exercise of convertible preferred stock warrants | ||||||||
| net liabilities assumed from business combination | ||||||||
| accrued transaction costs | ||||||||
| stock-based compensation expense | ||||||||
| issuance of convertible preferred stock warrants | ||||||||
| change in fair value of convertible promissory notes | ||||||||
| gain on early debt extinguishment | ||||||||
| interest expense | ||||||||
| proceeds from issuance of convertible preferred stock | ||||||||
| deferred rent | ||||||||
| accrued purchase of property and equipment | ||||||||
| accrued purchase of transaction costs | ||||||||
| conversion of promissory notes to convertible preferred stock | ||||||||
| settlement of accrued interest expense through conversion of promissory notes to convertible preferred stock | ||||||||
| adjustments to reconcile net income to net cash from operating activities: | ||||||||
| change in fair value of warrants | 117,485,000 | 50,845,000 | ||||||
| interest earned on marketable securities held in trust account | -6,900 | -61,910 | ||||||
| unrealized gain on marketable securities held in trust account | 0 | -9,455 | ||||||
| prepaid expenses | 44,738 | -13,909 | ||||||
| accounts payable and accrued expenses | ||||||||
| cash withdrawn from trust account to pay franchise and income taxes | ||||||||
| net change in cash | -162,150 | -467,993 | ||||||
| cash - beginning of period | 0 | 773,086 | ||||||
| cash - end of period | -162,150 | 305,093 | ||||||
| rsvac common stock shares outstanding prior to the merger | ||||||||
| less redemption of rsvac common stock shares | ||||||||
| rsvac common stock shares | ||||||||
| pipe shares issued | ||||||||
| merger and pipe shares | ||||||||
| legacy enovix common shares | ||||||||
| total shares of common stock immediately after the merger | ||||||||
| accrued expenses | 102,954 | |||||||
| cash withdrawn from trust account to pay taxes | 22,292 | |||||||
| · | ||||||||
| proceeds from paycheck protection program loan | ||||||||
| gain on extinguishment of the paycheck protection program loan | ||||||||
| common stock subject to possible redemption | ||||||||
| numerator: earnings allocable to common stock subject to possible redemption | ||||||||
| unrealized loss on marketable securities held in trust account | ||||||||
| net income allocable to shares subject to possible redemption | ||||||||
| denominator: weighted-average common stock subject to possible redemption | ||||||||
| basic and diluted weighted-average shares outstanding | ||||||||
| basic and diluted net income per share | ||||||||
| non-redeemable common stock | ||||||||
| numerator: net income minus net earnings | ||||||||
| net income allocable to common stock subject to possible redemption | ||||||||
| non-redeemable net income | ||||||||
| denominator: weighted-average non-redeemable common stock |
We provide you with 20 years of cash flow statements for Enovix stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Enovix stock. Explore the full financial landscape of Enovix stock with our expertly curated income statements.
The information provided in this report about Enovix stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.